Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
News about Werewolf Therapeutics, Inc. (Nasdaq: HOWL) centers on its progress in developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Company announcements frequently highlight updates from its PREDATOR platform, which is used to design INDUKINE cytokine prodrugs and INDUCER T cell engager candidates that aim to stimulate adaptive and innate immunity while limiting systemic toxicity.
Investors and followers of HOWL can expect regular news on the clinical development of WTX-124 and WTX-330, Werewolf’s most advanced INDUKINE programs. Press releases describe Phase 1/1b and Phase 1b/2 trial updates in multiple advanced solid tumors, regulatory designations such as Fast Track status for WTX-124 in cutaneous melanoma after standard immunotherapy, and emerging data on tolerability, antitumor activity, and tumor-selective activation strategies.
News flow also covers the company’s expanding INDUCER T cell engager platform, including preclinical data for WTX-1011, an anti‑STEAP1 candidate for STEAP1-expressing cancers, and WTX-2022, targeting CDH6-expressing cancers. Werewolf reports on presentations at scientific and medical meetings, such as the Society for Immunotherapy of Cancer’s Annual Meeting and disease-focused summits, where it shares data on sequential dosing of IL‑12 and IL‑2 INDUKINE molecules, masking strategies to reduce cytokine release, and real-time pharmacokinetic insights.
Additional HOWL news items include quarterly financial results, business updates, conference participation, and partnering discussions around its broader INDUKINE portfolio, including WTX-712, WTX-518, and WTX-921. For readers tracking immuno-oncology developments, the Werewolf Therapeutics news page provides a consolidated view of clinical milestones, regulatory interactions, scientific presentations, and corporate strategy disclosures related to the company’s conditionally activated immune therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.